SGLT-2 inhibitors, such as empagliflozin, dapagliflozin, provide cardiovascular benefits by reducing heart failure risk, improving endothelial function, and exerting anti-inflammatory effects [21]. This evidence concerns the gene SLC5A2 and heart failure.